Company profileNeural interface
Neurosoft Bioelectronics
Soft, stretchable electrode arrays for the brain surface, tested during surgery in people.
- Location
- Geneva, Switzerland
- Class
- Neural interfaceNot counted among core BCI companies.
- Funding stage
- Seed
- Sources last checked
- 4 Oct 2026
What they are building
EPFL spin-out in Geneva developing stretchable ECoG arrays that conform to the cortex and can be deployed through a small opening.
- Interface category
- Electrocorticography
- Signal
- Local field potentials, including high-gamma activity
- Invasiveness
- Invasive
- Recording / stimulation
- Recording
- Main use cases
- Monitor, Control
- Works with
- UTHealth Houston · UMC Utrecht · EPFL / Lausanne University Hospital
Where they are clinically
First-in-human
The first use of a device in a small number of people, focused on safety.
Human use has been during surgery for epilepsy or tumours. The arrays have not been implanted long term as a BCI.
Access today
Experimental human research
Demonstrated in a small number of research participants. Not an established treatment.
- Shown in people
- Stretchable arrays tested during surgery in ten patients across two studies, according to the company.
- Still an aim
- A long-term implant. Its current studies are surgical mapping.
- What stands in the way
- Chronic implantation, which has not been tried in people.
On record here: 0 peer-reviewed papers
This technology remains experimental and is not an established treatment. Access is limited to registered clinical studies.
Why this company matters
Neurosoft works on the layer under every surface BCI: the electrode material. Stretchable arrays that follow the brain's folds could widen coverage without widening the opening in the skull. It is an enabling-technology company for now, with human recordings but no chronic implant, and its current studies are in surgical mapping rather than BCI control.
Key milestones
20 May 2026
Seed round of $7.5 million led by Skybound Venture Capital; the company says its arrays have been tested in ten patients in two studies, at UTHealth Houston and UMC Utrecht.
Funding history
- 20 May 2026$7.5MSeed · led by Skybound Venture CapitalThe company puts total funding to date above $20M.
Investors namedSkybound Venture Capital · Protocol Labs · IAG Capital Partners · Connecticut Innovations
Rounds in the Briefing’s sample only; not a complete funding history.
Leadership
Nicolas Vachicouras
Co-founder and CEO
As publicly stated by the organisation. Not a complete list.
Competitive context
ECoGFirst-in-human
INBRAIN Neuroelectronics
Graphene-based cortical interfaces for high-resolution recording and stimulation.
ECoGApproved / cleared
Precision Neuroscience
A thin-film cortical surface array that slides under the skull through a narrow slit.
ECoGFirst-in-human
ABILITY Neurotech
A fully implanted ECoG system that sends raw neural data through the skin by infrared light.
Sources
- 01
Neurosoft Bioelectronics Closes $7.5M Oversubscribed Seed Round (opens in a new tab)
Company reportedNeurosoft Bioelectronics press release (via BioAlps)20 May 2026Checked against source 4 Oct 2026
Company release republished by a regional life-sciences association.